Key result
Inhibition of ACE2 by MLN-4760 increased the affinity of the SARS-CoV-2 spike protein binding to ACE2 and restored the enzymatic active conformation of ACE2 in molecular dynamics simulations.
Why the study?
Inhibition of ACE2 was proposed to block SARS-CoV-2 contagion, but whether ACE2 inhibition worsens or prevents infection remained controversial.
Does ACE2 inhibition by MLN-4760 affect the binding affinity of the SARS-CoV-2 spike protein to ACE2 in molecular dynamics simulations?
Does ACE2 inhibition by MLN-4760 affect the binding affinity of the SARS-CoV-2 spike protein to ACE2 in molecular dynamics simulations?
Answers are grounded in this paper and cite their sources.
Molecular dynamics simulations suggest that ACE2 inhibition by MLN-4760 increases the binding affinity of the SARS-CoV-2 spike protein to ACE2, potentially increasing infection risk.
BACKGROUND: Hypertension has been identified as the most common comorbidity in coronavirus disease 2019 (COVID-19) patients, and has been suggested as a risk factor for COVID-19 disease outcomes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host human cells via binding to host cell angiotensin-converting enzyme 2 (ACE2) receptors. Inhibition of ACE2 has been proposed as a potential therapeutic approach to block SARS-CoV-2 contagion. However, some experts suggest that ACE2 inhibition could worsen the infection. Here, we aimed to study the effect of ACE2 inhibition on the SARS-CoV-2 spike protein binding to ACE2. METHOD: Crystallographic structures of the SARS-CoV-2 spike protein, the spike receptor-binding domain, native ACE2, and the ACE2 complexed with MLN-4760 were used as the study model structures. The spike proteins were docked to the ACE2 structures and the dynamics of the complexes, ligand-protein, and protein-protein interactions were studied by molecular dynamics simulation for 100 ns. RESULTS: Our result showed that inhibition of ACE2 by MLN-4760 increased the affinity of the SARS-CoV-2 spike protein binding to ACE2. Results also revealed that spike protein binding to the ACE2 inhibited by MLN-4760 restored the enzymatic active conformation of the ACE2 from closed/inactive to open/active conformation by removing MLN-4760 binding from the ligand-binding pocket of ACE2. CONCLUSION: We conclude that using ACE2 inhibitors can increase the risk of SARS-CoV-2 infection and worsen COVID-19 disease outcome. We also found that the SARS-CoV-2 can abrogate the function of ACE2 inhibitors and rescue the enzymatic activity of ACE2. Therefore, ACE2 inhibition is not a useful treatment against COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
Nami et al. (2021) studied COVID-19. MLN-4760 (ACE2 inhibitor) vs. Native ACE2 was evaluated on Affinity of SARS-CoV-2 spike protein binding to ACE2 and conformational changes. Inhibition of ACE2 by MLN-4760 increased the affinity of the SARS-CoV-2 spike protein binding to ACE2 and restored the enzymatic active conformation of ACE2 in molecular dynamics simulations.
Synapse has enriched 10 related papers. Consider them for comparative context: